Search Results - "Persano, M."

Safe chemotherapy for treating early breast cancer in G6PD-deficient patients by Donisi, C., Atzori, F., Dessì, M., Persano, M., Scartozzi, M.

Get full text

Effectiveness of CA 19.9 in predicting prognosis in metastatic pancreatic cancer patients treated with nab-paclitaxel plus gemcitabine by Mariani, S., Soro, P., Liscia, N., Balconi, F., Camera, S., Donisi, C., Impera, V., Musio, F., Persano, M., Pireddu, A., Pretta, A., Tolu, S., Pusceddu, V., Lai, E., Faloppi, L., Demurtas, L., Ziranu, P., Puzzoni, M., Scartozzi, M.

Get full text

Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience by Pretta, A., Lai, E., Liscia, N., Impera, V., Camera, S., Musio, F., Mariani, S., Soro, P., Persano, M., Donisi, C., Tolu, S., Balconi, F., Atzori, F., Dessì, M., Massa, E., Madeddu, C., Pusceddu, V., Astara, G., Demurtas, L., Puzzoni, M., Ziranu, P., Scartozzi, M.

Get full text

Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset by Germani, M.M., Vetere, G., Santamaria, F., Intini, R., Ghelardi, F., Bensi, M., Boccaccino, A., Minelli, A., Carullo, M., Ciracì, P., Passardi, A., Santucci, S., Giampieri, R., Persano, M., Fenocchio, E., Puccini, A., Lonardi, S., Pietrantonio, F., Salvatore, L., Cremolini, C.

“…Targeted therapy (TT) with encorafenib and cetuximab is the current standard for patients with BRAFV600E-mutated metastatic colorectal cancer (mCRC) who…”
Get full text

Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience by Boccaccino, A., Borelli, B., Intini, R., Antista, M., Bensi, M., Rossini, D., Passardi, A., Tamberi, S., Giampieri, R., Antonuzzo, L., Noto, L., Roviello, G., Zichi, C., Salati, M., Puccini, A., Noto, C., Parisi, A., Rihawi, K., Persano, M., Crespi, V., Libertini, M., Giordano, M., Moretto, R., Lonardi, S., Cremolini, C.

“…Encorafenib plus cetuximab with or without binimetinib showed increased objective response rate (ORR), progression-free survival (PFS), and overall survival…”
Get full text

Estrogens as Antioxidant Modulators in Human Fertility by Mancini, Antonio, Raimondo, Sebastiano, Persano, M., Di Segni, C., Cammarano, M., Gadotti, G., Silvestrini, Andrea, Pontecorvi, Alfredo, Meucci, Elisabetta

“…Among treatments proposed for idiopathic male infertility, antiestrogens, like tamoxifen, play a possible role. On the other hand, oxidative stress is a…”
Get full text

Small intestinal obstruction secondary to kinetic sand ingestion in a dog by Trempe, Andrew J., Persano, Jeanine M.

“…Objective To describe a case of small intestinal obstruction secondary to kinetic sand ingestion in a dog. Animal An 11-year-old neutered male shih tzu dog…”
Get full text

Comparison of plasma antioxidant levels in middle-aged and old male with idiopatic osteoporosis: preliminary data by Mancini, A, Raimondo, S, Di Segni, C, Persano, M, Di Geronimo, E, Silvestrini, A, Pontecorvi, A, Meucci, E, Tamburrelli, F C

“…With the purpose of evaluating the role of oxidative stress (OS) in male idiopatic osteoporosis, we have evaluated plasma total antioxidant capacity (TAC) in…”
Get more information

72MO Clinical outcomes and response (R) with atezolizumab plus bevacizumab (AB) or lenvatinib (L) in hepatocellular carcinoma (HCC) by Persano, M., Rimini, M., Cascinu, S., Scartozzi, M., Casadei Gardini, A.

Get full text

105PSafe chemotherapy for treating early breast cancer in G6PD-deficient patients by Donisi, C, Atzori, F, Dessì, M, Persano, M, Scartozzi, M

Get full text

165P BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab by Amadeo, E., Persano, M., Tada, T., Suda, G., Shimose, S., Kudo, M., Yoo, C., Rossari, F., Vitiello, F., Casadei Gardini, A., Rimini, M.

Get full text

154P Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB) by Persano, M., Rimini, M., Tada, T., Suda, G., Shimose, S., Kudo, M., Yoo, C., Cheon, J., Finkelmeier, F., Lim, H.Y., Presa, J., Masi, G., Bergamo, F., Iavarone, M.A., Cabibbo, G., Foschi, F.G., Piscaglia, F., Cascinu, S., Scartozzi, M., Casadei Gardini, A.

Get full text

142P The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study by Rimini, M., Persano, M., Foti, S., Fornaro, L., Lonardi, S., Niger, M., Tamburini, E., Lavacchi, D., Rapposelli, I.G., Martinelli, E., Garajova, I., Simionato, F., Camera, S., Rossari, F., Amadeo, E., Vitiello, F., Cascinu, S., Rimassa, L., Antonuzzo, L., Casadei Gardini, A.

Get full text

170P Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population by Vitiello, F., Rimini, M., Persano, M., Suda, G., Shimose, S., Finkelmeier, F., Masi, G., Rossari, F., Amadeo, E., Casadei Gardini, A., Tada, T., Kudo, M., Cheon, J., Lim, H.Y., Yoo, C.

Get full text

185P Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study by Rossari, F., Tada, T., Shimose, S., Kudo, M., Yoo, C., Cheon, J., Finkelmeier, F., Lim, H.Y., Presa, J., Masi, G., Bergamo, F., Amadeo, E., Vitiello, F., Foti, S., Persano, M., Piscaglia, F., Scartozzi, M., Cascinu, S., Rimini, M., Casadei Gardini, A.

Get full text

188P Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab by Rimini, M., Amadeo, E., Vitiello, F., Foti, S., Persano, M., Tada, T., Suda, G., Shimose, S., Kudo, M., Cheon, J., Finkelmeier, F., Lim, H.Y., Piscaglia, F., Masi, G., Yoo, C., Lonardi, S., Rossari, F., Camera, S., Casadei Gardini, A., Presa, J.

Get full text

173P Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB) by Persano, M., Rimini, M., Tada, T., Suda, G., Shimose, S., Kudo, M., Yoo, C., Cheon, J., Finkelmeier, F., Lim, H.Y., Presa, J., Masi, G., Bergamo, F., Iavarone, M.A., Cabibbo, G., Foschi, F.G., Piscaglia, F., Cascinu, S., Scartozzi, M., Casadei Gardini, A.

Get full text

972P Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma by Persano, M., Rimini, M., Tada, T., Suda, G., Shimose, S., Kudo, M., Cheon, J., Finkelmeier, F., Presa, J., Masi, G., Yoo, C., Lonardi, S., Piscaglia, F., iavarone, M.A., TAMBURINI, E., Cabibbo, G., Silletta, M., Cascinu, S., Scartozzi, M., Casadei Gardini, A.

Get full text

P-90 Prognostic impact of depth of response (DpR) and early tumour shrinkage (ETS) in patients (pts) with BRAFV600E mutated (mut) metastatic colorectal cancer (mCRC) receiving targeted therapy (TT) as second-line treatment by Vetere, G., Germani, M., Bensi, M., Antoniotti, C., Lonardi, S., Passardi, A., Ghelardi, F., Calegari, M., Borelli, B., Santucci, S., Intini, R., Cristarella, E., Persano, M., Puccini, A., Lavacchi, D., Noto, L., Zichi, C., Giampieri, R., Salati, M., Cremolini, C.

Get full text

PD-15 Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments by Persano, M., Rimini, M., Toshifumi, T., Suda, G., Shigeo, S., Kudo, M., Cheon, J., Finkelmeier, F., Presa, J., Masi, G., Yoo, C., Lonardi, S., Tovoli, F., Piscaglia, F., Iavarone, M., Marra, F., Tamburini, E., Cabibbo, G., Scartozzi, M., Casadei-Gardini, A.

Get full text